**Background of Mitofusin2 Antibody**
Mitofusin2 (MFN2) is a mitochondrial outer membrane protein critical for regulating mitochondrial fusion, a key process in maintaining mitochondrial dynamics, morphology, and function. It belongs to the dynamin-related GTPase family and plays essential roles in energy metabolism, apoptosis, autophagy, and mitochondrial-ER interactions. MFN2 is encoded by the *MFN2* gene located on human chromosome 1p36.22. and its structural features include a highly conserved GTPase domain, heptad repeat regions, and transmembrane domains. Dysregulation or mutations in MFN2 are linked to various diseases, including Charcot-Marie-Tooth type 2A (CMT2A), diabetes, neurodegenerative disorders, and cardiovascular pathologies.
Mitofusin2 antibodies are immunological tools designed to detect and study the expression, localization, and interactions of MFN2 in cells and tissues. These antibodies are commonly used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to investigate mitochondrial dynamics in physiological and pathological contexts. They are often validated for specificity using knockout cell lines or tissues to ensure accurate detection. Polyclonal and monoclonal variants are available, targeting specific epitopes within the MFN2 protein. Research utilizing MFN2 antibodies has advanced understanding of mitochondrial quality control mechanisms, metabolic regulation, and disease pathways, making them vital reagents in studies related to aging, neurodegeneration, and metabolic syndromes. Proper validation and application of these antibodies remain crucial for reliable experimental outcomes.